You are here: Home » PTI Stories » National » News
Business Standard

Boehringer Ingelheim, Lupin sign pact for diabetes drug

Press Trust of India  |  New Delhi 

Drug firms Boehringer Ingelheim and have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India.

According to the agreement, "will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force," the companies said in a joint statement.



Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network, it added.

The companies, however, did not provide the financial details of the agreement.

The two companies had earlier signed a partnership for co-marketing Linagliptin in October 2015. The inclusion of Empagliflozin is a significant addition to the partnership, the statement said.

Commenting on the development, Regions Formulations Group President Shakti Chakraborty said: "We are happy to expand our partnership with Boehringer Ingelheim to combat growing menance of diabetes in India."

The Indian diabetes market is valued at Rs 9,003 crore, growing at 19.5 per cent as per IMS MAT July 2016, the statement said.

"This partnership shows our commitment towards addressing challenges in diabetes management in by providing broader access to innovative medicine," Boehringer Ingelheim Managing Director Sharad Tyagi said.

Boehringer Ingelheim will continue to introduce innovative products to address the unmet patients' needs amidst the growing Indian diabetes epidemic, he added.

Shares of Ltd today closed at Rs 1,480.40 per scrip on BSE, down 2.36 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Boehringer Ingelheim, Lupin sign pact for diabetes drug

Drug firms Boehringer Ingelheim and Lupin have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India. According to the agreement, "Lupin will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force," the companies said in a joint statement. Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network, it added. The companies, however, did not provide the financial details of the agreement. The two companies had earlier signed a partnership for co-marketing Linagliptin in October 2015. The inclusion of Empagliflozin is a significant addition to the partnership, the statement said. Commenting on the development, Lupin India Regions Formulations Group President Shakti Chakraborty said: "We are happy to expand our partnership with Boehringer Ingelheim to combat growing menance of ... Drug firms Boehringer Ingelheim and have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India.

According to the agreement, "will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force," the companies said in a joint statement.

Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network, it added.

The companies, however, did not provide the financial details of the agreement.

The two companies had earlier signed a partnership for co-marketing Linagliptin in October 2015. The inclusion of Empagliflozin is a significant addition to the partnership, the statement said.

Commenting on the development, Regions Formulations Group President Shakti Chakraborty said: "We are happy to expand our partnership with Boehringer Ingelheim to combat growing menance of diabetes in India."

The Indian diabetes market is valued at Rs 9,003 crore, growing at 19.5 per cent as per IMS MAT July 2016, the statement said.

"This partnership shows our commitment towards addressing challenges in diabetes management in by providing broader access to innovative medicine," Boehringer Ingelheim Managing Director Sharad Tyagi said.

Boehringer Ingelheim will continue to introduce innovative products to address the unmet patients' needs amidst the growing Indian diabetes epidemic, he added.

Shares of Ltd today closed at Rs 1,480.40 per scrip on BSE, down 2.36 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Boehringer Ingelheim, Lupin sign pact for diabetes drug

Drug firms Boehringer Ingelheim and have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India.

According to the agreement, "will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force," the companies said in a joint statement.

Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network, it added.

The companies, however, did not provide the financial details of the agreement.

The two companies had earlier signed a partnership for co-marketing Linagliptin in October 2015. The inclusion of Empagliflozin is a significant addition to the partnership, the statement said.

Commenting on the development, Regions Formulations Group President Shakti Chakraborty said: "We are happy to expand our partnership with Boehringer Ingelheim to combat growing menance of diabetes in India."

The Indian diabetes market is valued at Rs 9,003 crore, growing at 19.5 per cent as per IMS MAT July 2016, the statement said.

"This partnership shows our commitment towards addressing challenges in diabetes management in by providing broader access to innovative medicine," Boehringer Ingelheim Managing Director Sharad Tyagi said.

Boehringer Ingelheim will continue to introduce innovative products to address the unmet patients' needs amidst the growing Indian diabetes epidemic, he added.

Shares of Ltd today closed at Rs 1,480.40 per scrip on BSE, down 2.36 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard